A biologic tumor marker, also known as a biomarker, refers to a substance or molecule that can be measured in blood, body fluids, or tissues and is indicative of the presence or characteristics of a tumor or cancer. This marker is typically produced by cancer cells or as a response to the presence of a tumor within the body.
Biologic tumor markers can be either proteins, genes, hormones, enzymes, antibodies, or any other molecules that are associated with the development, progression, or regression of a tumor. These markers can be detected through various laboratory tests and imaging techniques, and their levels or presence can provide valuable information to help diagnose cancer, guide treatment decisions, monitor the effectiveness of treatment, and assess the risk of recurrence.
The specific biologic tumor marker used depends on the type of cancer being assessed. For example, prostate-specific antigen (PSA) is a well-known tumor marker used for prostate cancer, while carcinoembryonic antigen (CEA) is commonly used for colorectal cancer.
It is important to note that while certain biologic tumor markers are highly specific and sensitive for particular types of cancer, they are not definitive proof of the presence or absence of cancer. Further testing and evaluation are typically required to confirm a diagnosis or determine the stage and characteristics of the tumor.
Overall, biologic tumor markers play a crucial role in cancer detection, treatment planning, and patient follow-up, allowing for earlier diagnosis and personalized care, and improving the overall management and outcomes of cancer patients.
